Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question-Reference-Cited by-同舟云学术

Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question

Published:2015-10-22 Issue:12 Volume:29 Page:1128-1132
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Trifilio Steven¹,Zhou Zheng²,Galvin John²,Fong Jessica L.³,Monreal Joanne²,Mehta Jayesh²

Affiliation:

1. Department of Medicine and Pharmacy; Northwestern University; Chicago IL USA

2. Department of Medicine; Northwestern University; Chicago IL USA

3. Department of Pharmacy; Northwestern Hospital; Chicago IL USA

Publisher

Wiley

Subject

Transplantation

Reference23 articles.

1. Colony-stimulating factors for febrile neutropenia during cancer therapy;Bennett;N Engl J Med,2013

2. Will biosimilars gain momentum?;Hirsch;J Natl Compr Canc Netw,2013

3. Regulatory and clinical considerations for biosimilar oncology drug;Bennett;Lancet Oncol,2014

4. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy;Gatzemeier;J Thorac Oncol,2009

5. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy;Giglio;BMC Cancer,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans;BioDrugs;2023-04-01

3. Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System;Journal of Managed Care & Specialty Pharmacy;2017-12

4. Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation;Clinical Transplantation;2017-11-21

5. The Role of Biosimilars;Journal of the National Comprehensive Cancer Network;2016-05